Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clot regression with rivaroxaban in cancer-associated VTE
jRCTs051180077Completed
- Sponsor
- Bayer
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rivaroxaban in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE) and 1 more, sponsored by Bayer. Primary endpoint: Clot volume regression on CT. Started Oct 2018; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)cancer
Beyond the preview
Go deeper on jRCTs051180077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180077.